Current concerns of undertreatment and overtreatment in chronic myeloid leukemia based on European LeukemiaNet 2013 recommendations

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 15, 2013, Pages 2005-2010

  Haznedaroglu, Ibrahim C ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Chronic myeloid leukemia; Clinical trial; European LeukemiaNet 2013 recommendations; Tyrosine kinase inhibitor

Indexed keywords

BCR ABL PROTEIN; BOSUTINIB; CYTARABINE; DASATINIB; IMATINIB; INTERFERON; NILOTINIB; PEGINTERFERON; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

CANCER SURVIVAL; CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DRUG DOSE COMPARISON; DRUG TREATMENT FAILURE; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; KARYOTYPE; LEUKEMIA REMISSION; LUNG TOXICITY; MEDICAL DECISION MAKING; MEDICATION COMPLIANCE; METABOLIC SYNDROME X; PRACTICE GUIDELINE; REVIEW; TREATMENT RESPONSE;

HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; PROTEIN KINASE INHIBITORS;

EID: 84884572261     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.833185     Document Type: Review

References (18)

1. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013;122(6):872-84
2. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27(35):6041-51
3. Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 2010;116(19):3758-65
4. Baccarani M, Rosti G, Castagnetti F, et al. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia- positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood 2009;113(19):4497-504
5. Berger U, Engelich G, Reiter A, et al. Imatinib and beyond-the new CML study IV. A randomized controlled comparison of imatinib vs imatinib/interferon- alpha vs imatinib/low-dose AraC vs imatinib after interferon-alpha failure in newly diagnosed chronic phase chronic myeloid leukemia. Ann Hematol 2004;83(4):258-64
6. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362(24):2260-70
7. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362(24):2251-9
8. Hanfstein B, Muller M, Hehlmann R, et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 2012;26(9):2096-102
9. Yeung DT, Osborn MP, White DL, et al. Early switch to nilotinib does not overcome the adverse outcome for CML patients failing to achieve early molecular response on imatinib, despite excellent overall outcomes in the TIDEL II trial. ASH Annu Meet Abstr 2012;120(21):3771
10. Castagnetti F, Gugliotta G, Breccia M, et al. The BCR-ABL transcript levels at 3 and 6 months predict the long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib mesylate: a gimema CML WP analysis. ASH Annu Meet Abstr 2012;120(21):1678
11. Marin D, Hedgley C, Clark RE, et al. Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib. Blood 2012;120(2):291-4
12. Kantarjian H, O'Brien S, Jabbour E, et al. Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. J Clin Oncol 2011;29(23):3173-8
13. Hochhaus A, Hughes TP, Saglio G, et al. Outcome of patients with chronic myeloid leukemia in chronic phase (CML-CP) based on early molecular response and factors associated with early response: 4-year follow-up data from enestnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients). ASH Annu Meet Abstr 2012;120(21):167
14. Saglio G, Kantarjian HM, Shah N, et al. Early response (Molecular and Cytogenetic) and long-term outcomes in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): exploratory analysis of DASISION 3-year data. ASH Annu Meet Abstr 2012;120(21):1675
15. Mahon F-X, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010;11(11):1029-35
16. Cortes JE, Baccarani M, Guilhot F, et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 2010;28(3):424-30
17. Preudhomme C, Guilhot J, Nicolini FE, et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 2010;363(26):2511-21
18. Cortes JE, Kim DW, Kantarjian HM, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol 2012;28):3486-92